New pharmaceutical applications for macromolecular binders

JOURNAL OF CONTROLLED RELEASE

卷:155

Article; Proceedings Paper

Bertrand, Nicolas²  Gauthier, Marc A.¹  Bouvet, Celine²  Moreau, Pierre²  Petitjean, Anne³  Leroux, Jean-Christophe^1,2  Leblond, Jeanne² 

[1] ETH, Inst Pharmaceut Sci, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland

[2] Univ Montreal, Fac Pharm, Downtown Stn, Montreal, PQ H3C 3J7, Canada

[3] Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada

关键词: Polymeric drugs;    Polymeric binders;    Chelators;    Cyclodextrins;    Nanomedicine;   

DOI  :  10.1016/j.jconrel.2011.04.027

来源: Elsevier

【 摘 要 】

Macromolecular binders consist of polymers, dendrimers, and oligomers with binding properties for endogenous or exogenous substrates. This field, at the frontier of host/guest chemistry and pharmacology, has met a renewed interest in the past decade due to the clinical success of several sequestrants, like sevelamer hydrochloride (Renagel (R)) or sugammadex (Bridion (R)). In many instances, multivalent binding by the macromolecular drugs can modify the properties of the substrate, and may prevent it from reaching its site of action and/or trigger a biological response. From small (e. g., ions) to larger substrates (e. g., bacteria and cells), this review presents the state-of-the-art of macromolecular binders and provides detailed illustrative examples of recent developments bearing much promise for future pharmaceutical applications. (C) 2011 Elsevier B.V. All rights reserved.

【 授权许可】

Free